ZAP, an ISG evaluated in our previous and current study, was found to be negatively correlated with the susceptibility of hepatoma, colon cancer and bladder cancer cells to M1 oncolytic therapy18. This evidence concerns the gene ZC3HAV1 and hepatocellular carcinoma.